Protective effect of a marine oligopeptide preparation from chum salmon (Oncorhynchus keta) on radiation-induced immune suppression in mice.
BACKGROUND
A marine oligopeptide preparation (MOP) obtained from Chum Salmon (Oncorhynchus keta) by the method of enzymatic hydrolysis, has been found to enhance the innate and adaptive immunities through stimulation of the secretion of cytokines in mice. The current study aimed to further investigate the protective effect of MOP on radiation-induced immune suppression in mice.


RESULTS
Female ICR mice (6-8 weeks old) were randomly divided into three groups, i.e. blank control, irradiation control and MOP (1.350 g kg(-1) body weight) plus irradiation-treated group. MOP significantly increased the survival rate and prolonged the survival times for 30 days after irradiation, and lessened the radiation-induced suppression of T- or B-lymphocyte proliferation, resulting in the recovery of cell-mediated and humoral immune functions. This effect may be produced by augmentation of the relative numbers of radioresistant CD(4) (+) T cells, enhancement of the level of immunostimulatory cytokine, IL-12, reduction of the level of total cellular NF-κB through the induction of IκB in spleen and inhibition of the apoptosis of splenocytes.


CONCLUSIONS
We propose that MOP be used as an ideal adjuvant therapy to alleviate radiation-induced injuries in cancer patients.
Yang
Ruiyue
R
Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, PR China.
Pei
Xinrong
X
Wang
Junbo
J
Zhang
Zhaofeng
Z
Zhao
Haifeng
H
Li
Qiong
Q
Zhao
Ming
M
Li
Yong
Y
D000818:Animals; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000528:radiation effects*; D016516:CD4-CD8 Ratio; D049109:Cell Proliferation / Q000528:radiation effects; D016207:Cytokines / Q000097:blood / Q000378:metabolism; D019587:Dietary Supplements; D005260:Female; D005720:Gamma Rays / Q000009:adverse effects*; D020672:I-kappa B Proteins / Q000378:metabolism; D007108:Immune Tolerance / Q000187:drug effects; D051379:Mice; D008813:Mice, Inbred ICR; D000072000:NF-KappaB Inhibitor alpha; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D017685:Oncorhynchus keta; D011833:Radiation Injuries, Experimental / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D013154:Spleen / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000528:radiation effects*; D051996:Transcription Factor RelA / Q000378:metabolism
D051017:Apoptosis Regulatory Proteins; D016207:Cytokines; D020672:I-kappa B Proteins; C000606205:Nfkbia protein, mouse; D009842:Oligopeptides; D011837:Radiation-Protective Agents; C498144:Rela protein, mouse; D051996:Transcription Factor RelA; D000072000:NF-KappaB Inhibitor alpha